Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 41

Sort by

Sort Order Select

Journal Articles

Outcomes of PLAT-02 and PLAT-03: Evaluating CD19 CAR T-Cell Therapy and CD19-expressing T-APC Support in Pediatric B-ALL

Colleen Annesley, Kristy D. Seidel, Qian Wu, Corinne Summers, Alan S. Wayne, Michael A. Pulsipher, Anurag K Agrawal, Christopher T Brown, Stephanie Mgebroff, Catherine G Lindgren, Stephanie D. Rawlings-Rhea, Wenjun Huang, Ashley Wilson, Michael C Jensen, Julie R Park, Rebecca A Gardner

Blood blood.2025028359.

https://doi.org/10.1182/blood.2025028359

Published: 2025

Includes: Supplemental data

Journal Articles

A phase 1 trial of fully human BCMA CAR-T therapy for relapsed/refractory multiple myeloma with 5-year follow-up

Blood blood.2024027681.

https://doi.org/10.1182/blood.2024027681

Published: 2025

Includes: Supplemental data

Journal Articles

Venetoclax and Decitabine vs Intensive Chemotherapy as Induction for Young Patients with Newly Diagnosed AML

Blood blood.2024027217.

https://doi.org/10.1182/blood.2024027217

Published: 2025

Includes: Supplemental data

Journal Articles

Uncovering Therapeutic Resistance in BPDCN through Single-Cell Transcriptome Profiling

Ji Ma, Qiang He, Qian Wu, Lili Feng, Y. Lynn Wang, Linna Xie

Blood (2024) 144 (Supplement 1): 1557.

https://doi.org/10.1182/blood-2024-204227

Published: 2024

Journal Articles

Near early T-precursor lymphoblastic leukemia with marked flower petal nuclei: blast with unique cyanthiform nucleus

Qian Wu, Dong Chen

Blood (2024) 144 (17): 1846.

https://doi.org/10.1182/blood.2024026443

Published: 2024

Journal Articles

Machine Learning-Based Time-Series Clustering Identifies Archetypal Trajectories of Hematotoxicity after CAR T-Cell Therapy

Blood (2023) 142 (Supplement 1): 2143.

https://doi.org/10.1182/blood-2023-174106

Published: 2023

Journal Articles

Brentuximab Vedotin in Combination with Nivolumab in CD30+ Malignancies Refractory to Brentuximab Vedotin

Christina Poh, Ryan C Lynch, Edus H Warren, Chaitra S Ujjani, Stephen D Smith, Michi M Shinohara, Jonathan R Fromm, Xinyi Fan, Jenna M Voutsinas, Qian Wu, Laura Naylor, Heather Rasmussen, Ajay K Gopal

Blood (2023) 142 (Supplement 1): 3060.

https://doi.org/10.1182/blood-2023-178279

Published: 2023

Journal Articles

Improved Prevention and Treatment Strategy of Differentiation Syndrome Contribute to Reduce Early Death of Patients with Acute Promyelocytic Leukemia

Qian Wu, De-Pei Wu, Suning Chen, Xiaofei Yang, Jingren Zhang, Mengxing Xue, Xueqing Dou, Sheng-Li Xue, Huiying Qiu, Xiaowen Tang, Yue Han, Jianhong Fu, Xuefeng He

Blood (2023) 142 (Supplement 1): 1528.

https://doi.org/10.1182/blood-2023-182749

Published: 2023

Journal Articles

A Phase 2 Study of Nivolumab for Relapsed/Refractory Multiple Myeloma or Non-Hodgkin Lymphoma Following CAR-T Therapy

Blood (2023) 142 (Supplement 1): 3509.

https://doi.org/10.1182/blood-2023-173202

Published: 2023

Journal Articles

Phase 2 Study of Anakinra to Prevent CRS and Neurotoxicity after Treatment with Lisocabtagene Maraleucel: Planned Interim Analysis

Blood (2023) 142 (Supplement 1): 6848.

https://doi.org/10.1182/blood-2023-172695

Published: 2023

Journal Articles

Heterogeneity of TP53 Mutations in Mantle Cell Lymphoma- Challenges in Risk Stratification and Subclassification

Carrie I Ho, David Wu, Qian Wu, Kevin Ng, Jenna M Voutsinas, Ryan C Lynch, Manoj P Menon, Christina Poh, Mazyar Shadman, Brian G Till, Chaitra S Ujjani, Ajay K Gopal, Stephen D Smith

Blood (2023) 142 (Supplement 1): 3047.

https://doi.org/10.1182/blood-2023-181440

Published: 2023

Journal Articles

Acalabrutinib in Combination with Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory B-Cell Lymphoma: A Phase I/II Study of Safety, Efficacy and Immune Correlative Analysis

Christina Poh, Victor A Chow, Ryan C Lynch, Chaitra S Ujjani, Mazyar Shadman, Brian G Till, Vikram Raghunathan, Edus H Warren, Jordan Gauthier, Stephen D Smith, Taran Gujral, Chihiro Morishima, Qian Wu, Jenna M Voutsinas, Amy Sperling, Joshua Dizon, David G Maloney, Ajay K Gopal

Blood (2023) 142 (Supplement 1): 2129.

https://doi.org/10.1182/blood-2023-183034

Published: 2023

Journal Articles

Durable Remissions in Advanced Stage and Molecularly High Risk Untreated Classic Hodgkin Lymphoma with Pembrolizumab + AVD

Blood (2023) 142 (Supplement 1): 4429.

https://doi.org/10.1182/blood-2023-179547

Published: 2023

Journal Articles

Factors Associated with Prolonged CRS and Neurotoxicity after Treatment with Axicabtagene Ciloleucel

Aya Albittar, Jenna M Voutsinas, Andrew J Portuguese, Jennifer J. Huang, Emily C Liang, Qian Wu, Xinyi Fan, Alexandre V Hirayama, Erik L Kimble, Lorenzo Iovino, Christina Poh, Ajay K Gopal, Mazyar Shadman, Brian G Till, Filippo Milano, Aude G Chapuis, Ryan D Cassaday, David G Maloney, Jordan Gauthier

Blood (2023) 142 (Supplement 1): 2126.

https://doi.org/10.1182/blood-2023-180128

Published: 2023

Journal Articles

Association between Low Bone Mineral Density and Pain in a Prospective Cohort of Adults with Sickle Cell Disease: Preliminary Results from the SCD Bone Pain Study

Oyebimpe Adesina, Qian Wu, Leyla Y Teos, Mehrad Rokni, Lorenzo Nardo, Babette Zemel, Ted Wun

Blood (2023) 142 (Supplement 1): 3880.

https://doi.org/10.1182/blood-2023-174592

Published: 2023

Journal Articles

Intent to Treat Allogeneic Stem Cell Transplantation Outcomes in Relapsed/Refractory T-Cell Lymphomas

Christina Poh, Xinyi Fan, Jenna M Voutsinas, Qian Wu, Michi M Shinohara, Phuong T Vo, Mazyar Shadman, Chaitra S Ujjani, Ryan C Lynch, Brian G Till, Stephen D Smith, David G Maloney, Ajay K Gopal

Blood (2023) 142 (Supplement 1): 1708.

https://doi.org/10.1182/blood-2023-184314

Published: 2023

Journal Articles

Pembrolizumab with Rituximab in Relapsed/Refractory Follicular Lymphoma and Diffuse Large B Cell Lymphoma

Carrie I Ho, Ajay K Gopal, Chaitra S Ujjani, Ryan C Lynch, Christina Poh, Jenna M Voutsinas, Qian Wu, Jacquelin Vandermeer, Jonathan R Fromm, Stephen D Smith

Blood (2023) 142 (Supplement 1): 6144.

https://doi.org/10.1182/blood-2023-177682

Published: 2023

Journal Articles

Phase 2 Study of CD19 CAR T Cells with a Fully Human Binder for Large B-Cell Lymphoma in Relapse or Progression after a Murine Binder-Bearing CD19 CAR T-Cell Therapy

Blood (2023) 142 (Supplement 1): 6860.

https://doi.org/10.1182/blood-2023-181273

Published: 2023

Journal Articles

Phenotypic Analysis of Baseline T cell Subsets and Third Generation CD20 Targeted CAR T cell Products for Treatment of Relapsed/Refractory Follicular Lymphoma

George Mo, Sang Yun Lee, Jenna M Voutsinas, Qian Wu, Dong Hoon Lee, Jordan Gauthier, Alexandre V Hirayama, David G Maloney, Mazyar Shadman, Brian G Till

Blood (2023) 142 (Supplement 1): 6877.

https://doi.org/10.1182/blood-2023-180446

Published: 2023

Journal Articles

All-Trans-Retinoic Acid Induction Overcomes Immune Evasion through Downregulating Immune Checkpoint Molecules and Inducing a Cytokine Storm Triggered By Overexpression of S100A8/A9 Signaling

Blood (2023) 142 (Supplement 1): 4335.

https://doi.org/10.1182/blood-2023-184432

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Outcomes of PLAT-02 and PLAT-03: Evaluating CD19 CAR T-Cell Therapy and CD19-expressing T-APC Support in Pediatric B-ALL

A phase 1 trial of fully human BCMA CAR-T therapy for relapsed/refractory multiple myeloma with 5-year follow-up

Venetoclax and Decitabine vs Intensive Chemotherapy as Induction for Young Patients with Newly Diagnosed AML

Uncovering Therapeutic Resistance in BPDCN through Single-Cell Transcriptome Profiling

Near early T-precursor lymphoblastic leukemia with marked flower petal nuclei: blast with unique cyanthiform nucleus

Machine Learning-Based Time-Series Clustering Identifies Archetypal Trajectories of Hematotoxicity after CAR T-Cell Therapy

Brentuximab Vedotin in Combination with Nivolumab in CD30+ Malignancies Refractory to Brentuximab Vedotin

Improved Prevention and Treatment Strategy of Differentiation Syndrome Contribute to Reduce Early Death of Patients with Acute Promyelocytic Leukemia

A Phase 2 Study of Nivolumab for Relapsed/Refractory Multiple Myeloma or Non-Hodgkin Lymphoma Following CAR-T Therapy

Phase 2 Study of Anakinra to Prevent CRS and Neurotoxicity after Treatment with Lisocabtagene Maraleucel: Planned Interim Analysis

Heterogeneity of TP53 Mutations in Mantle Cell Lymphoma- Challenges in Risk Stratification and Subclassification

Acalabrutinib in Combination with Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory B-Cell Lymphoma: A Phase I/II Study of Safety, Efficacy and Immune Correlative Analysis

Durable Remissions in Advanced Stage and Molecularly High Risk Untreated Classic Hodgkin Lymphoma with Pembrolizumab + AVD

Factors Associated with Prolonged CRS and Neurotoxicity after Treatment with Axicabtagene Ciloleucel

Association between Low Bone Mineral Density and Pain in a Prospective Cohort of Adults with Sickle Cell Disease: Preliminary Results from the SCD Bone Pain Study

Intent to Treat Allogeneic Stem Cell Transplantation Outcomes in Relapsed/Refractory T-Cell Lymphomas

Pembrolizumab with Rituximab in Relapsed/Refractory Follicular Lymphoma and Diffuse Large B Cell Lymphoma

Phase 2 Study of CD19 CAR T Cells with a Fully Human Binder for Large B-Cell Lymphoma in Relapse or Progression after a Murine Binder-Bearing CD19 CAR T-Cell Therapy

Phenotypic Analysis of Baseline T cell Subsets and Third Generation CD20 Targeted CAR T cell Products for Treatment of Relapsed/Refractory Follicular Lymphoma

All-Trans-Retinoic Acid Induction Overcomes Immune Evasion through Downregulating Immune Checkpoint Molecules and Inducing a Cytokine Storm Triggered By Overexpression of S100A8/A9 Signaling

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only